

PRESS RELEASE

CMS Hasche Sigle
Partnerschaft von Rechtsanwälten
und Steuerberatern

Arndt Hellmann
Head of Public & Media Relations

Lennéstraße 7
10785 Berlin

T +49 30 20360 1208

F +49 30 20360 1299

E arndt.hellmann@cms-hs.com

www.cms-hs.com

Date	13 May 2013
Page	1 of 2
Subject	Capiton acquires majority stake in KD Pharma Bexbach

CMS Hasche Sigle advises capiton on acquisition of majority stake in KD Pharma Bexbach GmbH

Berlin – In conjunction with the management team, capiton has acquired 85% of the shares in KD Pharma Bexbach GmbH from the Bioseutica Group, which is retaining a 15% stake. The parties have not disclosed the purchase price.

KD Pharma Bexbach GmbH is a leading manufacturer of highly-enriched Omega-3 fatty acids, used as ingredients for food supplements and increasingly for medicines. KD Pharma Bexbach GmbH's unique patented production technology enables it to manufacture particularly high concentrations of Omega-3 fatty acids at up to 99% purity.

capiton is additionally investing a significant amount in expanding the production facilities at KD Pharma Bexbach GmbH, which are currently running at full capacity, with the aim of boosting capacity several fold over the next 12 months.

A team led by Berlin-based corporate law partner Ralf Kurney advised capiton on all legal aspects of the transaction. capiton is a longstanding CMS Hasche Sigle client.

capiton is an independent owner-managed private equity firm that supports established SMEs as an equity capital provider in the context of growth finance and management buy-outs.

Advisers CMS Hasche Sigle

Ralf Kurney, Corporate/M&A, Lead Partner

Christian Plodeck, Corporate/M&A

Dr Igor Stenzel, Corporate/M&A

Dr Tobias Teicke, Corporate/Compliance

Dr Jens Moraht, Finance

Jens Benninghofen, Finance

Prof. Winfried Bullinger, Patent Law

Dr Kai Hermes, Patent Law

Jesko Nobiling, Tax

Dr Nadja Fleischmann, Real Estate

Follow us on Twitter: <https://twitter.com/CMSHascheSigle>